Company intelligence / Profile preview

Aparito

Ownership: Private
Development stage: Other

Overview

Aparito is a digital health company specializing in digitizing clinical trials and real-world data capture, particularly for rare diseases. Its Atom5 platform enables remote patient monitoring, video assessments, and integration with wearable devices, providing real-time, continuous data to support clinical trials and routine care. Aparito was acquired by Eli Lilly in July 2024 and continues to expand its impact in decentralized and hybrid clinical trials[2][4][5].

Therapeutic areas: Infectious DiseasesNeurologyMetabolic DisordersRare Diseases
Modalities: Device
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Aparito.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aparito.

Explore the full profile